Aldeyra Therapeutics Announces Closing of Common Stock Offering

May 22, 2015

LEXINGTON, Mass., May 22, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that the underwriters for its recently completed underwritten public offering of common stock have partially exercised their option to purchase additional shares of common stock from Aldeyra. The underwriters purchased 122,500 additional shares from Aldeyra at the public offering price of $7.50 per share, less underwriting discounts and commissions.

Net proceeds to Aldeyra from the offering, including the sale of the additional shares, were approximately $19.9 million, after deducting underwriting discounts and commissions.

Cowen and Company, LLC and Canaccord Genuity Inc. acted as joint book-running managers and Janney Montgomery Scott LLC and Laidlaw & Company (UK) Ltd. acted as co-managers for the offering.

A registration statement relating to the offering was filed with the Securities and Exchange Commission on Form S-1, and declared effective on May 7, 2015. The offering was made by means of a prospectus. Copies of the prospectus related to the offering may be obtained from Cowen and Company, LLC on behalf of the underwriters, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by telephone at (631) 274-2806 or by fax at (631) 254-7140.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc., is a biotechnology company focused primarily on the development of products to treat diseases thought to be related to endogenous free aldehydes, a naturally occurring class of toxic molecules. The company has developed NS2, a product candidate designed to trap free aldehydes. Aldeyra has initiated clinical testing of NS2 for the treatment of Sjögren-Larsson Syndrome and noninfectious anterior uveitis. NS2 has not been approved for sale in the U.S. or elsewhere.   

CONTACT: Corporate Contact:

         Stephen TulipanoAldeyra Therapeutics, Inc.

         Tel: +1 781-761-4904 Ext. 205

         stulipano@aldeyra.com



         Investor Contact:

         David BurkeThe Ruth Group

         Tel: +1 646-536-7009

         dburke@theruthgroup.com
Source: Aldeyra Therapeutics

News Provided by Acquire Media

Safe Harbor Disclosure

This video content contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Aldeyra’s possible or assumed future results of operations, expenses and financing needs, business strategies and plans, research and development plans or expectations, trends, the structure, timing and success of Aldeyra’s planned or pending clinical trials, expected milestones, market sizing, pricing and reimbursement, competitive position, regulatory matters, industry environment and potential growth opportunities, among other things. Actual results or trends could differ materially from those contemplated by these forward-looking statements. For more information, please refer to the risk factors discussed in Aldeyra's periodic filings with the SEC, including the most recent Form 10-Q or 10-K. Any forward-looking statements that are made in the video content are based on assumptions as of the original date of the creation of such video, and Aldeyra undertakes no obligation to update these statements as a result of new information or future events.

Continue to video